The Company is a biotechnology company specializing in the development of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing. The Company uses its technology in the fields of clinical diagnostics. Its develops products for Thyroid, Fertility, Oncology, Vitamin D, Drugs of Abuse and other diseases. Its product, Vitamin D SMA is a steroid hormone involved in the intestinal absorption of calcium and the regulation of calcium homeostasis but it has also evolved into a hormone that has a diversity of biologic effects.
Farnham, GB
Size (employees)
16 (est)+15%
Bioventix is headquartered in Farnham, GB
Report incorrect company information

Bioventix Office Locations

Bioventix has an office in Farnham
Farnham, GB (HQ)
East St
Show all (1)
Report incorrect company information

Bioventix Financials and Metrics

Bioventix Financials

Bioventix's revenue was reported to be £7.25 m in FY, 2017

Revenue (FY, 2017)

7.2 m

Gross profit (FY, 2017)

6.8 m

Gross profit margin (FY, 2017), %


Net income (FY, 2017)

4.9 m

EBITDA (FY, 2017)

5.8 m

EBIT (FY, 2017)

5.7 m

Market capitalization (31-Oct-2017)

125.9 m

Closing share price (31-Oct-2017)


Cash (30-Jun-2017)

6.2 m
Bioventix's current market capitalization is £125.9 m.
GBPFY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017


1.6 m1.6 m2 m2.4 m2.7 m3.5 m4.3 m5.5 m7.2 m

Revenue growth, %


Cost of goods sold

160.4 k197.3 k236.3 k203.6 k188.3 k302.9 k320.5 k494.9 k494.9 k

Gross profit

1.5 m1.4 m1.7 m2.2 m2.5 m3.2 m4 m5 m6.8 m
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017


412.9 k1.2 m1.3 m1.5 m2.2 m2.6 m3.4 m4.1 m5.4 m6.2 m

Accounts Receivable

329.2 k68.5 k71.6 k180.4 k89.4 k343.1 k322.2 k389.1 k435.6 k451.8 k


79.1 k118.9 k90.2 k70.7 k85.7 k148.5 k164.1 k193 k198.9 k226.2 k

Current Assets

821.2 k1.8 m2 m2.4 m3.1 m4.1 m5.3 m6.4 m8.3 m9.7 m
GBPFY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

635.9 k564.4 k884.5 k1.2 m1.5 m1.8 m2.6 m3.5 m4.9 m

Cash From Operating Activities

867.3 k641 k1.1 m1.5 m1.3 m1.8 m2.9 m3.7 m5.2 m

Dividends Paid

58.5 k202 k524.1 k574.9 k656.3 k921.5 k1.3 m1.9 m3.4 m

Cash From Financing Activities

17.1 k(48.7 k)58.7 k21 k321.1 k
GBPY, 2017


483.1 k

Financial Leverage

1 x
Show all financial metrics

Bioventix Revenue Breakdown

Embed Graph

Bioventix revenue breakdown by business segment: 25.2% from Product revenue and R&D income and 74.8% from Royalty and licence fee income

Report incorrect company information